Condensed Consolidated Statements of Operations and Comprehensive Loss - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Operating expenses:
Research and development	$ 1,117,576	$ 6,015,616	$ 15,870,867	$ 19,433,721
General and administrative	3,082,618	3,414,795	18,849,549	10,183,953
Acquired in-process research and development			76,020,184
Total operating expenses	4,200,194	9,430,411	110,740,600	29,617,674
Other income (expense):
Interest income (expense), net	151,123	(33)	205,585	(1,678)
Foreign currency gain (loss)	24,353	(21,907)	315,130	247,233
Total other income (loss)	175,476	(21,940)	520,715	245,555
Net loss	(4,024,718)	(9,452,351)	(110,219,885)	(29,372,119)
Other comprehensive loss:
Foreign currency translation	26,161	(207,608)	118,311	(417,438)
Total comprehensive loss	$ (3,998,557)	$ (9,659,959)	$ (110,101,574)	$ (29,789,557)
Net loss per share attributable to common stockholders, basic (in dollars per share)	$ (0.12)	$ (0.45)	$ (4.17)	$ (1.39)
Net loss per share attributable to common stockholders, diluted (in dollars per share)	$ (0.12)	$ (0.45)	$ (4.17)	$ (1.39)
Weighted-average common shares outstanding, basic (in shares)	34,655,750	21,231,584	26,453,091	21,201,910
Weighted-average common shares outstanding, diluted (in shares)	34,655,750	21,231,584	26,453,091	21,201,910